Literature DB >> 2955417

Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit.

R Hohlfeld, K V Toyka, S J Tzartos, W Carson, B M Conti-Tronconi.   

Abstract

Myasthenia gravis is a human disease caused by an autoimmune response against the nicotinic acetylcholine receptor (AcChoR). Since the molecular structure of AcChoR is well known, myasthenia gravis is an excellent system for studying the recognition of a complex membrane antigen in the human immune system. Human T-helper (TH) cell lines reactive to the AcChoR were isolated from four myasthenic patients by selection with native AcChoR from Torpedo californica. The selected TH cells could efficiently recognize native and fully denatured AcChoR. The vast majority of the TH-stimulating AcChoR epitopes were located on the denatured alpha subunit of AcChoR. Antibody competition experiments using a panel of rat anti-AcChoR monoclonal antibodies showed that 39-45% of the autoantibodies present in the sera of these same patients bound to the conformation-sensitive "main immunogenic region" (MIR), also located on the alpha subunit. However, AcChoR-induced stimulation of the T cells could not be inhibited with up to 20-fold molar excess of different rat anti-MIR monoclonal antibodies. These results suggest that the Torpedo AcChoR alpha subunit contains conformation-insensitive epitopes that play a role in the autosensitization of TH cells and that seem to be physically separated from the MIR. The specificity of the TH cell response may contribute to directing the B-cell response to other alpha-subunit determinants, such as the MIR itself.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955417      PMCID: PMC298859          DOI: 10.1073/pnas.84.15.5379

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Inhibition of T cell proliferation by antibodies to synthetic peptides.

Authors:  J R Lamb; E D Zanders; P Lake; R G Webster; D D Eckels; J N Woody; N Green; R A Lerner; M Feldmann
Journal:  Eur J Immunol       Date:  1984-02       Impact factor: 5.532

2.  Ir-gene control of T cell proliferative responses: two distinct expressions of the genetically nonresponsive state.

Authors:  R M Maizels; J A Clarke; M A Harvey; A Miller; E E Sercarz
Journal:  Eur J Immunol       Date:  1980-07       Impact factor: 5.532

3.  Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor.

Authors:  S Tzartos; L Langeberg; S Hochschwender; J Lindstrom
Journal:  FEBS Lett       Date:  1983-07-11       Impact factor: 4.124

4.  Production and assay of antibodies to acetylcholine receptors.

Authors:  J Lindstrom; B Einarson; S Tzartos
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Subunit structure of the acetylcholine receptor from Electrophorus electricus.

Authors:  B M Conti-Tronconi; M W Hunkapiller; J M Lindstrom; M A Raftery
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies.

Authors:  S J Tzartos; D E Rand; B L Einarson; J M Lindstrom
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

7.  Autoimmune rat T lymphocytes monospecific for acetylcholine receptors: purification and fine specificity.

Authors:  R Hohlfeld; I Kalies; F Heinz; J R Kalden; H Wekerle
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

8.  Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Authors:  U A Besinger; K V Toyka; M Hömberg; K Heininger; R Hohlfeld; A Fateh-Moghadam
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

9.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

Authors:  A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

10.  Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.

Authors:  S J Tzartos; M E Seybold; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

View more
  19 in total

Review 1.  Intrathymic expression of neuromuscular acetylcholine receptors and the immunpathogenesis of myasthenia gravis.

Authors:  Arnold I Levinson; Yi Zheng; Glen Gaulton; Decheng Song; Jonni Moore; C Hank Pletcher
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Overexpression of select T cell receptor V beta gene families within CD4+ and CD8+ T cell subsets of myasthenia gravis patients: a role for superantigen(s)?

Authors:  D Gigliotti; A K Lefvert; M Jeddi-Tehrani; S Esin; V Hodara; R Pirskanen; H Wigzell; R Andersson
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

Review 4.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 5.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis.

Authors:  R Hohlfeld; K V Toyka; L L Miner; S L Walgrave; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

7.  A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.

Authors:  N Nagvekar; A M Moody; P Moss; I Roxanis; J Curnow; D Beeson; N Pantic; J Newsom-Davis; A Vincent; N Willcox
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

Review 8.  Vaccines against myasthenia gravis.

Authors:  Sonia Berrih-Aknin; Sara Fuchs; Miriam C Souroujon
Journal:  Expert Opin Biol Ther       Date:  2005-07       Impact factor: 4.388

9.  Presentation of endogenous acetylcholine receptor antigen to a specific CD4+ T-cell line by a transfected B-cell line.

Authors:  A F Mulcahy; D M Beeson; N Willcox; A G Diamond
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.

Authors:  M P Protti; A A Manfredi; X D Wu; L Moiola; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.